Farxiga Lawyers Reviewing Injury Lawsuits Nationwide
The product liability lawyers at Saiontz & Kirk, P.A. are reviewing potential Farxiga cases for individuals who have suffered kidney failure, a heart attack, stroke or been hospitalized due to ketoacidosis following use of this new diabetes drug.
Farxiga (dapagliflozin) was introduced by AstraZeneca in 2014 for treatment of type 2 diabetes. It is part of the same class of medications as Invokana, which has been linked to reports of serious and potentially life-threatening risks. It now appears likely that users may face a similar risk of Farxiga side effects that were not adequately disclosed on the drug warning label.
Financial compensation may be available through a Farxiga lawsuit for individuals who have suffered:
- Kidney Failure
- Heart Attack
- Wrongful Death
To review whether you, a friend or family member may be eligible to pursue a Farxiga injury case, request a free consultation and claim evaluation.
Farxiga Kidney Failure and Ketoacidosis Problems
The lawyers at Saiontz & Kirk are investigating Farxiga lawsuits for individuals throughout the United States.
Farxiga was approved by the FDA in 2014, after it was originally rejected three years earlier due to a lack of information on the safety and efficacy of the drug.
It is a member of a new class of diabetes drugs introduced in recent years, known as sodium-glucose co-transporter 2 (SGLT2) inhibitors.
The approval of Farxiga followed the approval of the Invokana as the first SGLT2 inhibitor in March 2013. As more individuals begin to use these new medications, signals of serious health risks have begun to emerge.
Farxiga and other SGLT2 inhibitors works by changing some normal kidney functions to increase the amount of sugar excreted in the urine. This was designed to increase glucose production and lower blood glucose levels among diabetics.
Although it appears that the drug makers knew or should have known about the potential injury risks with Farxiga before the medication was introduced, lawsuits will allege that AstraZeneca failed to adequately warn about all potential side effects.
SGLT2 inhibitors like Farxiga have been linked to hundreds of adverse event reports, including reports of:
- Kidney Failure
- Kidney Impairment
- Kidney Stones
- Urinary Tract Infections
- Abnormal Weight Loss
- Hypersensitivity Reactions
In addition, the FDA has expressed concerns that Farxiga may increase the risk of bladder cancer, causing the U.S. regulatory agency to initially reject the drug two years before it was approved.
Less than two years after Farxiga hit the market, the FDA issued a drug safety communication in May 2015, warning about reports of potential problems with Farxiga and other sodium-glucose co-transporter 2 (SGLT2) inhibiting diabetes drugs. The warning indicated that that the medication may cause patients to experience high levels of acid to accumulate in the blood; known as diabetic ketoacidosis, acidosis or ketosis.
In December 2015, the FDA expanded that Farxiga warning, urging patients to stop using the drug immediately and seek medical assistance if they began experiencing signs of ketoacidosis, like:
- Difficulty Breathing
- Nausea or Vomiting
- Abdominal Pain
- Confusion, Fatigue or Sleepiness
The FDA highlighted at least 73 adverse event reports received involving ketoacidosis with Farxiga or other similar diabetes drugs. Each of the cases resulted in hospitalization or emergency room treatment.
Allegations To Be Raised in Farxiga Lawsuits
- Failure to Study Farxiga Side Effects;
- Failure to Warn about Risk of Ketoacidosis, Heart Attacks, Strokes or Kidney Failure from Farxiga;
- Misrepresenting the Safety of Farxiga;
- Failure to Issue an Farxiga Recall
Farxiga Class Action Lawyers
Individuals hospitalized due to ketoacidosis or diagnosed with kidney failure, a heart attack or stroke may be entitled to financial compensation through an Farxiga class action lawsuit or individual injury claim.
The makers of Farxiga appear to have placed their desire for profits before consumer safety, by rushing the drug to market to gain an advantage over other competitor diabetes drugs.
As a result the drug maker failed to properly research the risk of DKA (diabetic ketoacidosis) or kidney failure, and withheld important safety information about the risk of serious and potentially life-threatening health problems from Farxiga.
The lawyers at Saiontz & Kirk, P.A. provide free consultations and claim evaluations to help individuals determine whether financial compensation may be available through a Farxiga settlement.
All lawsuits are pursued under a contingency fee agreement, which means that there are no out-of-pocket expenses to hire our Farxiga law firm and we only receive attorney fees or expenses if a recovery is obtained.